ATE318583T1 - Verfahren zur herstellung von partikeln mit einem aus dem amorphen und/oder metastabilen kristallinen zustand in einen kristallinen zustand überführten bereich - Google Patents

Verfahren zur herstellung von partikeln mit einem aus dem amorphen und/oder metastabilen kristallinen zustand in einen kristallinen zustand überführten bereich

Info

Publication number
ATE318583T1
ATE318583T1 AT99963731T AT99963731T ATE318583T1 AT E318583 T1 ATE318583 T1 AT E318583T1 AT 99963731 T AT99963731 T AT 99963731T AT 99963731 T AT99963731 T AT 99963731T AT E318583 T1 ATE318583 T1 AT E318583T1
Authority
AT
Austria
Prior art keywords
crystalline state
amorphic
particles
producing particles
metastable
Prior art date
Application number
AT99963731T
Other languages
English (en)
Inventor
Mikael Bisrat
Saeed Moshashee
Hakan Nyqvist
Mustafa Demirbueker
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed filed Critical
Application granted granted Critical
Publication of ATE318583T1 publication Critical patent/ATE318583T1/de

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/02—Nasal agents, e.g. decongestants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pulmonology (AREA)
  • Epidemiology (AREA)
  • Biochemistry (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Molecular Biology (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Immunology (AREA)
  • Otolaryngology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Polysaccharides And Polysaccharide Derivatives (AREA)
  • Inorganic Compounds Of Heavy Metals (AREA)
  • Oxygen, Ozone, And Oxides In General (AREA)
  • Physical Or Chemical Processes And Apparatus (AREA)
  • Crystals, And After-Treatments Of Crystals (AREA)
  • Saccharide Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Recrystallisation Techniques (AREA)
AT99963731T 1998-11-23 1999-11-22 Verfahren zur herstellung von partikeln mit einem aus dem amorphen und/oder metastabilen kristallinen zustand in einen kristallinen zustand überführten bereich ATE318583T1 (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
SE9804000A SE9804000D0 (sv) 1998-11-23 1998-11-23 New composition of matter

Publications (1)

Publication Number Publication Date
ATE318583T1 true ATE318583T1 (de) 2006-03-15

Family

ID=20413377

Family Applications (1)

Application Number Title Priority Date Filing Date
AT99963731T ATE318583T1 (de) 1998-11-23 1999-11-22 Verfahren zur herstellung von partikeln mit einem aus dem amorphen und/oder metastabilen kristallinen zustand in einen kristallinen zustand überführten bereich

Country Status (27)

Country Link
US (1) US6475524B1 (de)
EP (1) EP1133285B1 (de)
JP (1) JP4447169B2 (de)
KR (1) KR100697780B1 (de)
CN (1) CN1198592C (de)
AT (1) ATE318583T1 (de)
AU (1) AU767313B2 (de)
BR (1) BR9915592A (de)
CA (1) CA2349633C (de)
CY (1) CY1105609T1 (de)
CZ (1) CZ20011778A3 (de)
DE (1) DE69930158T2 (de)
DK (1) DK1133285T3 (de)
EE (1) EE200100275A (de)
ES (1) ES2258865T3 (de)
HU (1) HUP0104182A2 (de)
IL (2) IL143040A0 (de)
IS (1) IS5946A (de)
NO (1) NO20012514L (de)
NZ (1) NZ511494A (de)
PL (1) PL348523A1 (de)
PT (1) PT1133285E (de)
SE (1) SE9804000D0 (de)
SK (1) SK7032001A3 (de)
TR (1) TR200101424T2 (de)
WO (1) WO2000030614A1 (de)
ZA (1) ZA200103946B (de)

Families Citing this family (31)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0016002D0 (en) * 2000-06-29 2000-08-23 Glaxo Group Ltd Novel process for preparing crystalline particles
DE10062712A1 (de) * 2000-12-15 2002-06-20 Boehringer Ingelheim Pharma Neue Arzneimittelkompositionen auf der Basis von Anticholinergika und Corticosteroiden
EP1354581A4 (de) * 2000-12-26 2007-07-04 Takeda Pharmaceutical Poröse substanz und verfahren zu ihrer herstellung
US7276190B2 (en) * 2001-07-02 2007-10-02 Micro & Nano Materials Sagl Process for the production of micro and/or nano particles
GB0126716D0 (en) * 2001-11-07 2002-01-02 Advanced Phytonics Ltd Method for the production of particles
PE20040950A1 (es) 2003-02-14 2005-01-01 Theravance Inc DERIVADOS DE BIFENILO COMO AGONISTAS DE LOS RECEPTORES ADRENERGICOS ß2 Y COMO ANTAGONISTAS DE LOS RECEPTORES MUSCARINICOS
RU2006132043A (ru) * 2004-02-06 2008-03-20 МЕДА Фарма ГмбХ унд Ко.КГ (DE) Комбинация и фармацевтический препарат для лечения ринита
TWI341836B (en) 2004-03-11 2011-05-11 Theravance Inc Biphenyl compounds useful as muscarinic receptor antagonists
WO2005105065A2 (en) 2004-05-05 2005-11-10 Renopharm Ltd. Thiazole-based nitric oxide donors for treating inflammatory bowel diseases
US7498445B2 (en) 2004-05-05 2009-03-03 Renopharm Ltd. Thiazole-based nitric oxide donors capable of releasing two or more nitric oxide molecules and uses thereof
US8134010B2 (en) 2004-05-05 2012-03-13 Renopharm Ltd. Thiazole-based nitric oxide donors having aryl substituent(s) and uses thereof
US7968575B2 (en) 2004-05-05 2011-06-28 Renopharm Ltd. Nitric oxide donors and uses thereof
WO2006023460A2 (en) 2004-08-16 2006-03-02 Theravance, Inc. COMPOUNDS HAVING β2 ADRENERGIC RECEPTOR AGONIST AND MUSCARINIC RECEPTOR ANTAGONIST ACTIVITY
JP5000095B2 (ja) * 2005-03-11 2012-08-15 花王株式会社 有機結晶粒子の製造方法
EP1904219A4 (de) 2005-07-15 2011-07-27 Map Pharmaceuticals Inc Teilchenbildungsverfahren
DE102006030166A1 (de) * 2006-06-29 2008-01-10 Boehringer Ingelheim Pharma Gmbh & Co. Kg Tempern
WO2009047935A1 (ja) * 2007-10-12 2009-04-16 Ono Pharmaceutical Co., Ltd. 微粒子
PL2229233T3 (pl) * 2007-12-07 2020-03-31 Xspray Pharma Ab (Publ) Sposób wytwarzania cząstek
JP5138670B2 (ja) * 2009-01-30 2013-02-06 三洋化成工業株式会社 樹脂粒子およびその製造方法
EP3620154A1 (de) 2009-02-06 2020-03-11 University Of Southern California Therapeutische zusammensetzungen mit monoterpenen
SI2453894T1 (sl) 2009-07-15 2016-02-29 Theravance Biopharma R&D Ip, Llc Kristalinična oblika proste baze bifenilne spojine
CA2828833C (en) 2010-03-03 2020-11-03 Neonc Technologies Inc. Pharmaceutical compositions comprising monoterpenes
US20160038600A1 (en) 2012-08-03 2016-02-11 Neonc Technologies Inc. Pharmaceutical compositions comprising poh derivatives
ES2600928T3 (es) 2010-08-27 2017-02-13 Neonc Technologies Inc. Composiciones farmacéuticas que comprenden derivados de alcohol perilílico
WO2012083178A1 (en) 2010-12-17 2012-06-21 Neo Oncology Inc. Methods and devices for using isoperillyl alcohol
SI2968313T1 (en) 2013-03-15 2018-05-31 Verona Pharma Plc Combination of medicines
GB201402556D0 (en) 2014-02-13 2014-04-02 Crystec Ltd Improvements relating to inhalable particles
PL3231444T3 (pl) 2014-05-12 2020-05-18 Verona Pharma Plc Nowe leczenie
EP3872069A1 (de) 2015-02-12 2021-09-01 Neonc Technologies, Inc. Pharmazeutische zusammensetzungen mit perillylalkoholderivaten
CN110267538B (zh) 2016-11-30 2022-04-19 尼昂克技术公司 紫苏醇-3-溴丙酮酸缀合物和治疗癌症的方法
BR112020016074A2 (pt) 2018-02-08 2020-12-08 Neonc Technologies, Inc Métodos de permeabilização da barreira hematoencefálica

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SE9302777D0 (sv) * 1993-08-27 1993-08-27 Astra Ab Process for conditioning substances
SE9101090D0 (sv) 1991-04-11 1991-04-11 Astra Ab Process for conditioning of water-soluble substances
US5639441A (en) 1992-03-06 1997-06-17 Board Of Regents Of University Of Colorado Methods for fine particle formation
GB9313642D0 (en) * 1993-07-01 1993-08-18 Glaxo Group Ltd Method and apparatus for the formation of particles
GB9413202D0 (en) * 1994-06-30 1994-08-24 Univ Bradford Method and apparatus for the formation of particles
ATE212545T1 (de) 1995-03-28 2002-02-15 Fidia Advanced Biopolymers Srl Nanosphären mit einem biokompatiblen polysaccharid
DE69828155T2 (de) 1997-03-20 2005-12-22 Schering Corp. Herstellung von pulveragglomeraten

Also Published As

Publication number Publication date
TR200101424T2 (tr) 2001-12-21
CY1105609T1 (el) 2010-07-28
SE9804000D0 (sv) 1998-11-23
PT1133285E (pt) 2006-06-30
DK1133285T3 (da) 2006-06-06
JP2002530319A (ja) 2002-09-17
SK7032001A3 (en) 2001-11-06
AU767313B2 (en) 2003-11-06
EP1133285B1 (de) 2006-03-01
ES2258865T3 (es) 2006-09-01
EP1133285A1 (de) 2001-09-19
CA2349633C (en) 2009-06-02
NO20012514D0 (no) 2001-05-22
IS5946A (is) 2001-05-18
EE200100275A (et) 2002-10-15
DE69930158T2 (de) 2006-11-16
CA2349633A1 (en) 2000-06-02
DE69930158D1 (de) 2006-04-27
WO2000030614A1 (en) 2000-06-02
CN1328447A (zh) 2001-12-26
KR20010080534A (ko) 2001-08-22
KR100697780B1 (ko) 2007-03-21
NZ511494A (en) 2003-11-28
JP4447169B2 (ja) 2010-04-07
US6475524B1 (en) 2002-11-05
BR9915592A (pt) 2001-08-07
IL143040A (en) 2009-09-01
NO20012514L (no) 2001-07-19
ZA200103946B (en) 2002-10-30
IL143040A0 (en) 2002-04-21
CN1198592C (zh) 2005-04-27
CZ20011778A3 (cs) 2001-08-15
PL348523A1 (en) 2002-06-03
HUP0104182A2 (hu) 2002-03-28
AU2010400A (en) 2000-06-13

Similar Documents

Publication Publication Date Title
DE69930158D1 (de) Verfahren zur herstellung von partikeln mit einem aus dem amorphen und/oder metastabilen kristallinen zustand in einen kristallinen zustand überführten bereich
DE60216830D1 (de) Pharmazeutische Zusammensetzungen zur Behandlung von Störungen des ZNS oder anderen Erkrankungen
DE60134453D1 (de) Pharmazeutische Zusammensetzungen zur Behandlung von ZNS und anderen Krankheiten
SE9804001D0 (sv) New process
EP1467627A4 (de) Verfahren zur verarbeitung von ginseng sowie anwendungen für extrakt aus verarbeitetem ginseng
DE60018881D1 (de) Extrakte von mutterkraut (tanacetum parthenium) gegen entzündliche erkrankungen
CA2171882A1 (en) Inhibitors of .beta.-amyloid protein production
DE10337184A1 (de) Substituierte 3-Pyrrolidin-Indol-Derivate
ATE161273T1 (de) Polysaccharidderivate von heparin, heparansulfate, ihre fraktionen und fragmente, verfahren zu deren herstellung und pharmazeutische zusammensetzungen, welche diese enthalten
DE68904672D1 (de) Halbleiteranordnung, deren struktur die wirkung des parasitischen transistors erschwert und verfahren zur herstellung.
ATE234089T1 (de) Zubereitungen enthaltend sclareol und sclareolide zur behandlung mikrobieller infektionen
HUP0102009A1 (hu) Szintetikus poliszacharidok, előállítási eljárásuk, valamint az ezeket tartalmazó gyógyszerkompozíciók
DE59402607D1 (de) Verfahren zur herstellung von granulaten
WO2001001974A3 (en) Naaladase inhibitors in anxiety and memory disorders
ATE245445T1 (de) Suspension enthaltend ein epi-hne protein, verfahren zu ihrer herstellung, daraus hergestelltes trockenpulveraerosol, arzneimittelzusammensetzungen enthaltend diese suspension oder dieses aerosol und ihre verwendungen
DE69005557D1 (de) Substituierte 4-Amino-2-butinyl-Harnstoffe und -thioharnstoffe sowie deren Derivate als zentral wirkende muscarinische Mittel.
BR9912581A (pt) Processos para tratar ou prevenir um distúrbio causado por disfunção da motilidade gastrointestinal em um humano e para elicitar um efeito procinético em um humano, e, composição farmacêutica
ATE294582T1 (de) Verwendung von alpha-1-adrenorezeptor- antagonisten zur herstellung eines medikaments für die vorbeugung und die behandlung von krebs
ATE402253T1 (de) Humane adulte astrozyten, sowie deren herstellung und verwendung
WO2002076437A3 (en) Methods for treating neurodegenerative diseases including alzheimer's
DE69434002D1 (de) 2,3 diaryl-1-benzopyrame zur behandlung von dermatitis
WO2004012710A8 (en) Crystalline drug particles prepared using a controlled precipitation (recrystallization) process
ATE259784T1 (de) Propanolaminotetraline, verfahren zu ihrer herstellung sowie diese verbindungen enthaltende pharmazeutische zusammensetzungen
DE69524737D1 (de) 2-isoxazolin-derivate, verfahren zu deren herstellung sowie verfahren zur herstellung von verwandten verbindungen

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification

Ref document number: 1133285

Country of ref document: EP

REN Ceased due to non-payment of the annual fee